CD19 and diffuse large B-cell lymphoma: However, Strati et al were the first to report the safe treatment of a patient who was HBsAg positive with diffuse large B cell lymphoma (DLBCL) with CD19 CAR-T cells.36 This patient remained on tenofovir prescribed at the same dose, before and after the CAR-T cells infusion.